Company:  LPATH, INC (LPTN)
Form Type:  10-K
Filing Date:  3/23/2011 
CIK:  0001251769 
Address:  4025 SORRENTO VALLEY BLVD. 
City, State, Zip:  SAN DIEGO, California 92121-1404 
Telephone:  858-678-0800 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.20  
Change: 
0.15 (7.32%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$5.20M
Trade LPTN now with

© 2016  
Description of Business
We are a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. We have developed three drug candidates, advancing each of them into clinical trials, and built evidence to support our approach of targeting bioactive lipids to treat a wide range of diseases. In January 2016, we completed the dosing of all subjects in our Phase 1 clinical trial of Lpathomab. As of December 31, 2015, we had cash and cash equivalents totaling $8.9 million. We have incurred significant net losses since our inception. To conserve our cash resources, we have reduced our headcount and limited our research and product development activities. As a result of these actions, we believe our current resources should be sufficient to fund our operations through the third quarter of 2016.
Register and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
        NAME AND TITLE
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS
    Report of Independent Registered Public Accounting Firm
    SIGNATURES
  EXHIBIT 10.19
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED ...